Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089856 · ClinicalTrials.gov registry record · Phase 3
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
A Phase 3 study, sponsored by Cell Genesys.
- Terminated
- Registry status
- Phase 3
- Development phase
- 626
- Enrollment target
NCT00089856: Clinical Trial Phase 3 study, sponsored by Cell Genesys.
NCT00089856 is a Phase 3 study that was terminated before completion, run by Cell Genesys. The registered enrollment target is 626 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089856, a Phase 3 study, was terminated before completion, sponsored by Cell Genesys.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 626 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.
Interventions
- BIOLOGICAL Immunotherapy with allogeneic prostate vaccine
- DRUG Chemotherapy (Taxotere and prednisone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 626 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Why NCT00089856 stopped before completion
NCT00089856 is an interventional study that assigns participants to a tested intervention. The registered 626 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 2 interventions - of which Immunotherapy with allogeneic prostate vaccine is the first listed.
NCT00089856 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00089856 about?
NCT00089856 is a clinical study titled "GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer". The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in th...
What is the current status of trial NCT00089856?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 626 participants. The study started on 2004-07. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00089856?
The interventions under investigation include: Immunotherapy with allogeneic prostate vaccine (BIOLOGICAL), Chemotherapy (Taxotere and prednisone) (DRUG).
Who is sponsoring clinical trial NCT00089856?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00089856's enrollment target sits among peer trials
626 586th of 2000 higher than 1,415 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia